Arterius

Arterius is a private, pre-revenue medical device company developing next-generation, patient-centric solutions for arterial disease, primarily peripheral arterial disease (PAD). The company has built two synergistic polymer technology platforms: a drug-coated balloon (DCB) coating for efficient single or dual-drug transfer to the vessel wall, and the ArterioSorb™ bioresorbable scaffold, a fully resorbable stent designed to provide temporary support. Founded in 2015 and based in Leeds, UK, Arterius has raised over £10 million in grants and equity, achieved ISO 13485 certification, and is planning First-in-Human studies for its lead products.

Two advanced polymer platforms: 1) A proprietary coating for efficient single/dual-drug delivery from balloons to vessel walls, and 2) The ArterioSorb™ bioresorbable scaffold (stent) made via a patented solid-phase orientation process, designed to fully resorb after 3-6 months.

Arterius competes in the crowded peripheral vascular device market against major players like Boston Scientific, Medtronic, and Philips, who dominate with metal stents and DCBs. In bioresorbable scaffolds, it faces the challenge of reviving a skeptical market following the failure of first-generation coronary BVS products, though the peripheral space is less saturated. Its differentiation hinges on proving superior drug transfer and scaffold mechanics.